Mirati Therapeutics (MTRX) PT Cut to $7 at Piper Jaffray
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Piper Jaffray analyst Steven Breazzano slashed his price target on Mirati Therapeutics (NASDAQ: MRTX) to $7.00 (from $14.00) while keeping a Neutral rating following Q2 results.
Breazzano commented, "After the close, MRTX reported 2Q earnings and provided several corporate updates. Following the update at ASCO earlier this year and subsequent reformulation of lead drug glesatinib into a spray-dried dispersion (SDD) to reduce GI side effects, MRTX continues to enroll patients and plans to provide an update once enough clinical data has been obtained, which may occur later this year. Though promising, questions still remain concerning the drug's profile and LT differentiation in this crowded field, and we remain on the sidelines given the competitive landscape and early stage of the clinical assets. Reiterate Neutral rating, though our PT moves to $7/share from $14/share reflecting changes to our model, see below for details."
Shares of Mirati Therapeutics closed at $5.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- Jefferies Raises Price Target on Symantec (SYMC) to $27; Reiterates Hold
- UBS Downgrades Dynegy (DYN) to Sell
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Analyst PT Change
Related EntitiesPiper Jaffray, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!